Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: A Canadian perspective

Bone Marrow Transplantation

Volumn 22, Issue 12, 1998, Pages 1199-1205

  Couban, S ^a   Dranitsaris, G ^b   Andreou, P ^a   Price, S ^b   Tinker, L ^b   Foley, R ^c   Walker, I R ^c   Jamal, S ^b   Jamal, N ^b   Spaner, D ^b   Lipton, J ^b   Meharchand, J ^b   Messner, H A ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Allogeneic peripheral blood transplant; Economic analysis

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BONE MARROW TRANSPLANTATION; CANADA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ECONOMIC ASPECT; FEMORAL VEIN; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEMATOPOIETIC STEM CELL; HUMAN; NEUTROPHIL; PRIORITY JOURNAL; RISK; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THROMBOCYTE; TIME; VEIN CATHETERIZATION;

EID: 0032425786     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701504     Document Type: Article

References (21)

1. Korbling M, Dorken B, Ho AD et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986; 67: 529-532.
2. Kessinger A, Armitage JO, Landmark JD et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723-727.
3. To LB, Shepperd KM, Haylock DN et al. Single high-dose cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442-447.
4. Gianni AM, Bregni M, Stern AC et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; ii: 580-585.
5. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation vs autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
6. Korbling M, Przepiorka D, Hug YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
7. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
8. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
9. Miflin G, Russell NH, Hutchinson RM et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997; 19: 9-13.
10. Pavletic ZS, Bishop MR, Tarantolo SR et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation in patients with hematologic malignancies. J Clin Oncol 1997; 15: 1608-1616.
11. Przepiorka D, Anderlini P, Ippoliti C et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant 1997; 19: 455-460.
12. Majolino I, Saglio G, Scimè R et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell (PBSC) transplantation in patients with hematologic malignancies. Blood 1995; 86 (Suppl.): 108a (Abstr. 420).
13. Couban S, Simpson DR, Bredeson C et al. First 100 donors in the Canadian Bone Marrow Transplant Group trial comparing peripheral blood and bone marrow in allogeneic transplant. Bone Marrow Transplant 1998; 21 (Suppl. 1): S36 (Abstr. 128).
14. Fyles GM, Messner HA, Lockwood G et al. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high-dose rate. Bone Marrow Transplant 1991; 8: 453-463.
15. + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
16. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Atkinson K, Horowitz MM, Gale RP et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 1989; 4: 247-254.
18. Russell JA, Brown C, Bowen T et al. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996; 17: 703-708.
19. Lane T. Allogeneic marrow reconstitution using peripheral blood stem cells: the dawn of a new era. Transfusion 1996; 36: 585-589.
20. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-1415.
21. Smith TJ, Hillner BE, Schmitz N et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral blood progenitor cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10.